HIPK1 Inhibition Protects against Pathological Cardiac Hypertrophy by Inhibiting the CREB‐C/EBPβ Axis
Y Bei, Y Zhu, M Wei, M Yin, L Li, C Chen… - Advanced …, 2023 - Wiley Online Library
Inhibition of pathological cardiac hypertrophy is recognized as an important therapeutic
strategy for heart failure, although effective targets are still lacking in clinical practice …
strategy for heart failure, although effective targets are still lacking in clinical practice …
HIPK1 Inhibition Protects against Pathological Cardiac Hypertrophy by Inhibiting the CREB-C/EBPβ Axis.
Y Bei, Y Zhu, M Wei, M Yin, L Li, C Chen… - Advanced Science …, 2023 - europepmc.org
Inhibition of pathological cardiac hypertrophy is recognized as an important therapeutic
strategy for heart failure, although effective targets are still lacking in clinical practice …
strategy for heart failure, although effective targets are still lacking in clinical practice …
HIPK1 Inhibition Protects against Pathological Cardiac Hypertrophy by Inhibiting the CREB-C/EBPβ Axis
Y Bei, Y Zhu, M Wei, M Yin, L Li… - Advanced science …, 2023 - pubmed.ncbi.nlm.nih.gov
Inhibition of pathological cardiac hypertrophy is recognized as an important therapeutic
strategy for heart failure, although effective targets are still lacking in clinical practice …
strategy for heart failure, although effective targets are still lacking in clinical practice …
HIPK1 Inhibition Protects against Pathological Cardiac Hypertrophy by Inhibiting the CREB-C/EBPβ Axis
Y Bei, Y Zhu, W Meng, M Yin, L Li, C Chen… - Advanced …, 2023 - search.proquest.com
Inhibition of pathological cardiac hypertrophy is recognized as an important therapeutic
strategy for heart failure, although effective targets are still lacking in clinical practice …
strategy for heart failure, although effective targets are still lacking in clinical practice …
[HTML][HTML] HIPK1 Inhibition Protects against Pathological Cardiac Hypertrophy by Inhibiting the CREB‐C/EBPβ Axis
Y Bei, Y Zhu, M Wei, M Yin, L Li, C Chen… - Advanced …, 2023 - ncbi.nlm.nih.gov
Inhibition of pathological cardiac hypertrophy is recognized as an important therapeutic
strategy for heart failure, although effective targets are still lacking in clinical practice …
strategy for heart failure, although effective targets are still lacking in clinical practice …
HIPK1 Inhibition Protects against Pathological Cardiac Hypertrophy by Inhibiting the CREB-C/EBPβ Axis.
Y Bei, Y Zhu, M Wei, M Yin, L Li, C Chen… - Advanced Science …, 2023 - europepmc.org
Inhibition of pathological cardiac hypertrophy is recognized as an important therapeutic
strategy for heart failure, although effective targets are still lacking in clinical practice …
strategy for heart failure, although effective targets are still lacking in clinical practice …